ライフサイエンスコーパス: angiogenesis inhibitor

1 ngle 5 (K5) of human plasminogen is a potent angiogenesis inhibitor.

2 id solenopsin, and found that it is a potent angiogenesis inhibitor.

3 oliferating hemangioma, are stimulated by an angiogenesis inhibitor.

4 ilin-2 (NRP2), a novel mechanism for a tumor angiogenesis inhibitor.

5 fumagillin derivative and a well-established angiogenesis inhibitor.

6 -kDa fragment of collagen XVIII, is a potent angiogenesis inhibitor.

7 lecule isocoumarin, is a recently discovered angiogenesis inhibitor.

8 and vascular tone, is a naturally occurring angiogenesis inhibitor.

9 ic administration of TNP-470, a conventional angiogenesis inhibitor.

10 point and the effectiveness of TNP-470 as an angiogenesis inhibitor.

11 e metastatic site and not from a circulating angiogenesis inhibitor.

12 in three tumour types treated with a potent angiogenesis inhibitor.

13 nts to a role for protein S as an endogenous angiogenesis inhibitor.

14 Maspin has been identified as a potent angiogenesis inhibitor.

15 C-terminal domain of perlecan, is a powerful angiogenesis inhibitor.

16 matrix protein, thrombospondin 1 (TSP1), an angiogenesis inhibitor.

17 teinases-3 (TIMP-3) is a potent matrix-bound angiogenesis inhibitor.

18 es of endothelial cells after treatment with angiogenesis inhibitors.

19 provide biomarkers for treatment efficacy of angiogenesis inhibitors.

20 ranol may serve as a lead for a new class of angiogenesis inhibitors.

21 ise a major source of small molecular weight angiogenesis inhibitors.

22 nding of the downstream molecular targets of angiogenesis inhibitors.

23 esting novel approaches to the generation of angiogenesis inhibitors.

24 c system may function as naturally occurring angiogenesis inhibitors.

25 epresent a new target for the development of angiogenesis inhibitors.

26 ions of anticancer drugs coadministered with angiogenesis inhibitors.

27 e IV may represent an important new class of angiogenesis inhibitors.

28 nhibit this interaction are a novel class of angiogenesis inhibitors.

29 he mechanisms of tumor growth suppression by angiogenesis inhibitors.

30 r proteins that are themselves not active as angiogenesis inhibitors.

31 impact as a noninvasive method for assessing angiogenesis inhibitors.

32 tions involved in the acquired resistance to angiogenesis inhibitors.

33 enic mediators and a concomitant decrease in angiogenesis inhibitors.

34 ially useful tool for assessing responses to angiogenesis inhibitors.

35 endent transduction of signals by endogenous angiogenesis inhibitors.

36 ficant toxicities associated with the use of angiogenesis inhibitors.

37 is among the most potent and broad-spectrum angiogenesis inhibitors.

38 prospectively assessed in clinical trials of angiogenesis inhibitors.

39 as potential targets for the development of angiogenesis inhibitors.

40 Here we identify brain-specific angiogenesis inhibitor 1 (BAI1) as a receptor upstream o

41 Here, we identify brain-specific angiogenesis inhibitor 1 (BAI1) as a synaptic adhesion G

42 emonstrated that mice lacking brain-specific angiogenesis inhibitor 1 (BAI1) have severe deficits in

43 ssessed the expression and function of brain angiogenesis inhibitor 1 (BAI1) in the engulfment of apo

44 Brain angiogenesis inhibitor 1 (BAI1) is a putative G protein-

45 Brain angiogenesis inhibitor 1 (BAI1) is a receptor that recog

46 Brain angiogenesis inhibitor 1 (BAI1) is a transmembrane prote

47 Brain angiogenesis inhibitor 1 (BAI1) is a transmembrane prote

48 Brain-specific angiogenesis inhibitor 1 (BAI1), an orphan G protein-cou

49 olves the phagocytic receptor brain-specific angiogenesis inhibitor 1 (BAI1), which recognizes phosph

50 Two of these proteins, brain-specific angiogenesis inhibitor 1 and protein kinase Calpha, co-i

51 ult ADHD and the gene BAIAP2 (brain-specific angiogenesis inhibitor 1-associated protein 2), even aft

52 Brain angiogenesis inhibitor-1 (BAI1) is a brain-predominant s

53 Brain-specific angiogenesis inhibitor-1 (BAI1) is an adhesion G protein

54 of nintedanib (BIBF 1120), a small molecule angiogenesis inhibitor, 10 weeks post-injection suppress

55 Interestingly, the endogenous angiogenesis inhibitor 2-methoxyestradiol augments FasL/

56 dometriosis-associated angiogenesis, and the angiogenesis inhibitor 2-methoxyestradiol may be a poten

57 Systemic treatment with the angiogenesis inhibitor 2-methoxyestradiol suppressed HIF

58 ql1 specifically binds to the brain-specific angiogenesis inhibitor 3 (Bai3), which is a member of th

59 s, anginex shares with several physiological angiogenesis inhibitors a dependence on plasma adhesion

60 o target vessel wall neovascularization with angiogenesis inhibitors, a therapeutic approach that has

61 eolytic fragment of plasminogen, is a potent angiogenesis inhibitor able to suppress tumor growth and

62 Endogenous angiogenesis inhibitors act as tumor suppressor proteins

63 ture, but there are only limited data on how angiogenesis inhibitors affect the tumor uptake of these

64 Mice were treated with a combination of the angiogenesis inhibitor AGM-1470 (TNP-470), the antibioti

65 egnant cycling mice after treatment with the angiogenesis inhibitor AGM-1470.

66 wo-thirds hepatectomy, or treatment with the angiogenesis inhibitor, AGM-1470,O-chloroacetyl-carbamoy

67 However, treatment with angiogenesis inhibitors alone did not significantly affe

68 Kinesin-derived angiogenesis inhibitor also inhibits VEGF-induced EC mig

69 mitogen-activated protein kinase and a known angiogenesis inhibitor, also blocked the observed VEGF-i

70 eal a novel function for angioarrestin as an angiogenesis inhibitor and indicate that the molecule ma

71 metastatic 4T1 breast tumor using SU6668, an angiogenesis inhibitor and recombinant murine (rm) B7.2-

72 hway have potential pharmacologic utility as angiogenesis inhibitors and antineoplastic agents.

73 ude that adipose tissue mass is sensitive to angiogenesis inhibitors and can be regulated by its vasc

74 Since combination regimens using angiogenesis inhibitors and cytotoxic drugs will be need

75 ay be critical for developing biomarkers for angiogenesis inhibitors and improving combination regime

76 rogation of the changes in the expression of angiogenesis inhibitors and in situ hybridization studie

77 ood vessel growth is regulated by endogenous angiogenesis inhibitors and matrix constituents, as well

78 or (ATR) ligands, such as PA and PASSSR, are angiogenesis inhibitors and that ATRs are useful targets

79 y be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potenti

80 New angiogenesis inhibitors and vascular disrupting agents h

81 It is not known how angiogenesis inhibitors and vascular disrupting agents u

82 hrombotic and hemorrhagic complications from angiogenesis inhibitors and vascular disrupting agents,

83 ntrast, most localized tumors expressed this angiogenesis inhibitor, and a significant correlation be

84 ndothelial growth factor as an example of an angiogenesis inhibitor, and agents targeting the epiderm

85 ssibility for the combination of TNP-470, an angiogenesis inhibitor, and temozolomide (TMZ), a DNA-al

86 such as prodrug-converting enzymes, toxins, angiogenesis inhibitors, and cytokines.

87 suggest a theme of fragments of proteins as angiogenesis inhibitors, and demonstrate dormancy therap

88 ted in other tumor types), responsiveness to angiogenesis inhibitors, and resistance to both chemothe

89 alpha(v)beta(3) antagonists are potent angiogenesis inhibitors, and several different classes o

90 The angiogenesis inhibitor angiostatin reduces plaque angiog

91 eported the identification of the endogenous angiogenesis inhibitor angiostatin, a specific inhibitor

92 at individual MMPs also regulate the natural angiogenesis inhibitor angiostatin.

93 We previously identified the angiogenesis inhibitor angiostatin.

94 he crystal structure of the human Pg-derived angiogenesis inhibitor, angiostatin, complexed to VEK-30

95 ma plasminogen is the precursor of the tumor angiogenesis inhibitor, angiostatin.

96 Angiogenesis inhibitors are a novel class of promising t

97 Novel angiogenesis inhibitors are being studied in the treatme

98 Many angiogenesis inhibitors are breakdown products of endoge

99 A group of angiogenesis inhibitors are derived from fragments of ex

100 Several angiogenesis inhibitors are fragments of larger proteins

101 Some of these angiogenesis inhibitors are in clinical trials, but a cl

102 Angiogenesis inhibitors are now widely used in the clini

103 Angiogenesis inhibitors are receiving increased attentio

104 However, the benefits of angiogenesis inhibitors are typically transient and resi

105 Many more agents, particularly angiogenesis inhibitors, are in early clinical developme

106 tration improves the antitumoral efficacy of angiogenesis inhibitors, as compared with intermittent d

107 ts components, and tested them using the SVR angiogenesis inhibitor assay.

108 ), also known as soluble VEGF receptor 1, an angiogenesis inhibitor associated with preeclampsia.

109 h as site and stage, and therapies including angiogenesis inhibitors associated with higher risk of V

110 treated so as to compare the effects of four angiogenesis inhibitors at three distinct stages of dise

111 Brain angiogenesis inhibitors (BAI) are putative transmembrane

112 he G-protein coupled receptor brain-specific angiogenesis inhibitor (BAI3) as a cell surface protein

113 cancer patients treated with the widely used angiogenesis inhibitor bevacizumab in combination with c

114 ollagen XVIII, has been shown to be a potent angiogenesis inhibitor both in vivo and in vitro when gi

115 Sema3s function as potent endogenous angiogenesis inhibitors but require proteolytically proc

116 To investigate whether expression of an angiogenesis inhibitor by cancer cells could alter this

117 The production of angiogenesis inhibitors by the primary tumor is one mech

118 e tested the proposition that treatment with angiogenesis inhibitors can inhibit the progression of t

119 trix homeostasis, together with a loss of an angiogenesis inhibitor, can prime vascular beds to be mo

120 These results suggest that 3TSR, or other angiogenesis inhibitors, can be repurposed for TSP1 repl

121 Through treatment with angiogenesis inhibitors capillary permeability may be re

122 Systemic treatment with the angiogenesis inhibitors caplostatin and endostatin pepti

123 fortunately, emerging evidence confirms that angiogenesis inhibitors cause cardiac complications, inc

124 vitation of lesions in clinical trials of an angiogenesis inhibitor combined with chemotherapy for no

125 rowth factor (VEGF) Trap (aflibercept) is an angiogenesis inhibitor comprising portions of the extrac

126 Angiogenesis inhibitors could reverse these processes, r

127 ectives on the mechanisms of failure of anti-angiogenesis inhibitors currently in use.

128 results reveal upregulation of an endogenous angiogenesis inhibitor during multi step tumorigenesis a

129 is are well established, those of endogenous angiogenesis inhibitors (EAIs) remain to be fully elabor

130 ) or with cells engineered to overexpress an angiogenesis inhibitor--either tissue inhibitor of matri

131 monocyte activating polypeptide II, another angiogenesis inhibitor, elicited the same response in th

132 s study was to investigate the effect of the angiogenesis inhibitor Endostar on carotid plaque neovas

133 d treatment of allograft recipients with the angiogenesis inhibitor endostatin failed to inhibit leuk

134 These data suggest that the angiogenesis inhibitor endostatin levels may locally mod

135 assessed the effect of local delivery of the angiogenesis inhibitor endostatin on human glioma cell l

136 hanced migratory activity in response to the angiogenesis inhibitor endostatin, to determine if HemEP

137 gioma endothelial cells is stimulated by the angiogenesis inhibitor endostatin, unlike the inhibition

138 XC chemokine/CXCL5) and up-regulation of the angiogenesis inhibitor endostatin.

139 , CXCL16, and CXCL5 and up-regulation of the angiogenesis inhibitor endostatin.

140 n alpha(5)beta(1) is also the target for the angiogenesis inhibitor, endostatin.

141 owever, the mechanism by which these diverse angiogenesis inhibitors exert their common effects remai

142 LMWH and ursolic acid (UA), which is also an angiogenesis inhibitor for tumor therapy.

143 e importance of the research in the field of angiogenesis inhibitors for future oncologic therapy.

144 Angiogenesis inhibitors for the treatment of cancer have

145 presents the first demonstration of multiple angiogenesis inhibitors from a single tumor and suggests

146 ong-term, in vivo expression of a functional angiogenesis inhibitor has been established using rAAV,

147 A class of angiogenesis inhibitor has emerged from our mechanistic

148 mbospondin-1 (THBS1), a P53 and Rb regulated angiogenesis inhibitor, has been observed in some human

149 vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerability and promi

150 Two angiogenesis inhibitors have been developed that have a

151 More than 300 angiogenesis inhibitors have been discovered to date; 80

152 n these findings, several clinical trials of angiogenesis inhibitors have been initiated in human mel

153 Angiogenesis inhibitors have been shown to transiently n

154 Angiogenesis inhibitors have gained much public attentio

155 umors such as renal cell carcinoma; however, angiogenesis inhibitors have not been particularly succe

156 Although angiogenesis inhibitors have provided substantial clinic

157 Angiogenesis inhibitors have shown clinical activity in

158 hat the fifth member, BAIAP3 (brain-specific angiogenesis inhibitor I-associated protein 3), acts in

159 pproaches targeting the DNA damage response, angiogenesis inhibitors, immune checkpoint inhibitors, o

160 Many new techniques such as gene therapy, angiogenesis inhibitors, immunotherapy, and others that

161 Additionally, maspin acts as an angiogenesis inhibitor in rat cornea model and in a xeno

162 The efficacy of angiogenesis inhibitors in cancer is limited by resistan

163 Thus angiogenesis inhibitors in combination with inhibitors o

164 address this issue, we screened a variety of angiogenesis inhibitors in developing zebrafish and chic

165 eview the rationale and recent experience of angiogenesis inhibitors in malignant gliomas and to high

166 ew summarizes the most important findings on angiogenesis inhibitors in NSCLC and discusses the poten

167 l trials of these agents and discuss the new angiogenesis inhibitors in preclinical development.

168 A variety of well characterized angiogenesis inhibitors (including angiostatin, fumagill

169 us endothelial checkpoints, and resistant to angiogenesis inhibitors independent of myeloid cells.

170 Similar increases were achieved using other angiogenesis inhibitors, indicating that increased drug

171 ibitor of metalloproteinase 2 (TIMP-2) is an angiogenesis inhibitor initially characterized for its a

172 One of the best-studied angiogenesis inhibitors is endostatin, which acts throug

173 ctor, but its role in signal transduction by angiogenesis inhibitors is less clear.

174 Pazopanib, an oral angiogenesis inhibitor, is approved for the treatment of

175 TIMP3, which encodes a potent angiogenesis inhibitor, is mutated in Sorsby fundus dyst

176 se data demonstrate that soluble VEGFR-1, an angiogenesis inhibitor, is regulated in skeletal muscle

177 23-amino acid peptide termed kinesin-derived angiogenesis inhibitor (KAI) not only prevents interacti

178 tment of endometriosis-bearing mice with the angiogenesis inhibitor Lodamin, an oral nontoxic formula

179 This downregulation of an angiogenesis inhibitor may, in turn, play a critical rol

180 fore, VEGF upregulation of ADAMTS1, a potent angiogenesis inhibitor, may represent a mechanism for fe

181 eas less-specific targeted agents, including angiogenesis inhibitors (median RR, 3.39; P < .001) and

182 and suggest that therapeutic application of angiogenesis inhibitors might potentially be associated

183 We report the formal synthesis of angiogenesis inhibitor NM-3 (1) in six steps from either

184 Treatment with a clinically approved angiogenesis inhibitor normalized angiogenic signature m

185 ted a potential drug interaction between the angiogenesis inhibitor O-(N-chloroacetyl-carbamoyl)-fuma

186 e have identified angiostatin, an endogenous angiogenesis inhibitor of 38 kDa which specifically bloc

187 Our data suggest that VEGI is a novel angiogenesis inhibitor of the TNF family and functions i

188 leukemia, with an emphasis on modulators of angiogenesis, inhibitors of the ubiquitin-proteasome pat

189 herosclerosis, we investigated the effect of angiogenesis inhibitors on plaque growth in apoE -/- mic

190 angiogenesis stimulator) and endostatin (an angiogenesis inhibitor), or for thrombospondin-1 and bas

191 dase-2 (MetAP-2), which covalently binds the angiogenesis inhibitor ovalicin.

192 Here, we identify the angiogenesis inhibitor pigment epithelium-derived factor

193 of the anti-angiogenic signal by the natural angiogenesis inhibitor, pigment epithelial-derived facto

194 Two angiogenesis inhibitors, pigment epithelium-derived fact

195 ), to address the role that these endogenous angiogenesis inhibitors play in tumor growth.

196 indomethacin (2 mg/kg/day), or the specific angiogenesis inhibitor PPI-2458 (5 mg/kg every other day

197 A brief treatment with the angiogenesis inhibitor PPI-2458 (5 mg/kg orally on alter

198 by systemic administration of 3 doses of the angiogenesis inhibitor PPI-2458 during the acute phase.

199 strategy, we have identified endostatin, an angiogenesis inhibitor produced by hemangioendothelioma.

200 Angiogenesis inhibitors produced by a primary tumor can

201 Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free surviv

202 Prolonged treatment with either angiogenesis inhibitor reduced plaque growth and intimal

203 We conclude that angiogenesis inhibitors, regardless of the molecular tar

204 The results suggest that angiogenesis inhibitors represent a valid component of a

205 Several types of angiogenesis inhibitors reveal a biphasic, U-shaped curv

206 Angiogenesis inhibitor's pharmacodynamic actions on tumo

207 27a/b promotes angiogenesis by targeting the angiogenesis inhibitor SEMA6A, which controls repulsion

208 ally, miR-27 regulated the expression of the angiogenesis inhibitor semaphorin 6A (SEMA6A) in vitro a

209 Angiogenesis inhibitors show promise, but evaluation for

210 nts for activity of thalidomide analogues as angiogenesis inhibitors, since there is only speculative

211 This new approach for targeting angiogenesis inhibitors specifically to the tumor vascul

212 ly indicator of response to tyrosine kinase (angiogenesis) inhibitors such as pazopanib in ovarian ca

213 Angiogenesis inhibitors, such as O-(chloracetyl-carbamoy

214 ing the pharmacological response and dose of angiogenesis inhibitors, such as PTK/ZK, for further cli

215 lidate a strategy for identifying endogenous angiogenesis inhibitors, suggest a theme of fragments of

216 targeting the yeast pathway that also act as angiogenesis inhibitors suitable for chemotherapy.

217 This explains why ovalicin and related anti-angiogenesis inhibitors target Type II human MetAP but n

218 PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting all known vascular endo

219 Pazopanib, an angiogenesis inhibitor targeting VEGF receptor, PDGF rec

220 LC) patients treated with pazopanib, an oral angiogenesis inhibitor targeting VEGFR, platelet-derived

221 Clinical efficacy of angiogenesis inhibitors targeting the vascular endotheli

222 Endostatin, an angiogenesis inhibitor tested in multiple clinical trial

223 m has been a significant complication of the angiogenesis inhibitors thalidomide and lenalidomide.

224 d RSI were lower in tumors overexpressing an angiogenesis inhibitor than in control tumors (all P < .

225 Tumstatin is an angiogenesis inhibitor that binds to alphavbeta3 integri

226 An orally available angiogenesis inhibitor that can be used in conjunction w

227 Thrombospondin 1 (TSP1) is an angiogenesis inhibitor that decreases tumor growth.

228 iculin inclusive of amino acids 1-180, is an angiogenesis inhibitor that exerts antitumor effects in

229 one-related peptide is a naturally occurring angiogenesis inhibitor that functions by activation of p

230 ADAMTS9 as a novel, constitutive, endogenous angiogenesis inhibitor that operates cell-autonomously i

231 is based on the discovery of angiostatin, an angiogenesis inhibitor that selectively instructs endoth

232 gs demonstrate that NM-3 is a well-tolerated angiogenesis inhibitor that significantly increases the

233 As an angiogenesis inhibitor that specifically targets prolife

234 hese data suggest that the combination of an angiogenesis inhibitor that targets endothelial cells wi

235 We evaluated sunitinib, an angiogenesis inhibitor that targets VEGF and PDGF recept

236 A variety of angiogenesis inhibitors that antagonize the effects of v

237 ctly contribute to the antitumor activity of angiogenesis inhibitors that block the VEGFR2 pathway.

238 Angiogenesis inhibitors that block VEGF receptor (VEGFR)

239 common effector molecules used by a panel of angiogenesis inhibitors that perturb the cytoskeleton to

240 angiogenesis by modulating the level of the angiogenesis inhibitor thrombospondin 2 (TSP2).

241 umors was associated with down-regulation of angiogenesis inhibitor thrombospondin and decreased sens

242 died the expression and biologic role of the angiogenesis inhibitor thrombospondin-1 (TSP-1) during t

243 Methylation-associated inactivation of the angiogenesis inhibitor thrombospondin-1 (TSP-1) has been

244 The function of the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-1) in epith

245 The roles played by the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-1) in the e

246 The function of the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-1) in tissu

247 the lung, which exhibits high levels of the angiogenesis inhibitor thrombospondin-1 (TSP-1).

248 we found that explants from mice lacking the angiogenesis inhibitor thrombospondin-1 (TSP1) exhibit e

249 d by a strong reduction in the levels of the angiogenesis inhibitor thrombospondin-1 (TSP1), but the

250 he production and delivery of the endogenous angiogenesis inhibitor thrombospondin-1 by platelets may

251 erol levels also increased the levels of the angiogenesis inhibitor thrombospondin-1 in the xenograft

252 in-specific overexpression of the endogenous angiogenesis inhibitor thrombospondin-1 were subjected t

253 ly 92 microRNA cluster and downregulates the angiogenesis inhibitor thrombospondin-1, along with othe

254 onin, unlike VEGF-A, up-regulated the potent angiogenesis inhibitor thrombospondin-1, thereby trigger

255 tor and an increase in the production of the angiogenesis inhibitor thrombospondin-1.

256 tor and an increase in the production of the angiogenesis inhibitor thrombospondin-1.

257 cidate the biological role of the endogenous angiogenesis inhibitor thrombospondin-2 (TSP-2) during m

258 investigate the biologic role of the potent angiogenesis inhibitor thrombospondin-2 (TSP-2) in the c

259 arcoma secrete relatively high levels of the angiogenesis inhibitors thrombospondin-1 and TIMP-1.

260 The matricellular angiogenesis inhibitor, thrombospondin (TSP) 2, has been

261 anied by a dramatic decline in the levels of angiogenesis inhibitor, thrombospondin-1 (TSP1).

262 Mice that lack the matricellular angiogenesis inhibitor, thrombospondin-2 (TSP2), display

263 6 E6 and E7, expression levels of two potent angiogenesis inhibitors, thrombospondin-1 and maspin, we

264 te that expression of one of the most potent angiogenesis inhibitors, thrombospondin-1, is up-regulat

265 represses thrombospondin-1 (TSP1), a potent angiogenesis inhibitor, through epigenetic regulation.

266 (bFGF) (1 microg/g/d intraperitoneal) or the angiogenesis inhibitor TNP-470 (30 mg/kg/qod subcutaneou

267 he toxicity and pharmacokinetics (PK) of the angiogenesis inhibitor TNP-470 and secondarily to evalua

268 atment of established murine tumors with the angiogenesis inhibitor TNP-470 caused near-complete abla

269 When another angiogenesis inhibitor, TNP-470, was added to the antian

270 thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the treatment of ca

271 Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials.

272 pondins 1 and 2 were among the first natural angiogenesis inhibitors to be identified.

273 e, there is a need for small molecule ocular angiogenesis inhibitors to complement existing therapies

274 rtant when assessing novel compounds such as angiogenesis inhibitors to optimize the dose and schedul

275 Evolutions in angiogenesis inhibitor treatments for cancer and other d

276 ted reduced protein, not mRNA, expression of angiogenesis inhibitors TSP-1 and thrombospondin-2 (TSP-

277 tment modalities such as metronomic therapy, angiogenesis inhibitors, vascular disrupting agents and

278 To determine the effects of the angiogenesis inhibitor vasostatin, a 180 amino acid calr

279 Further, a differential sensitivity to angiogenesis inhibitors was seen between strains, with o

280 Endostatin, a potent angiogenesis inhibitor, was administered to mice bearing

281 ion of the thrombospondin-1 (TSP-1) gene, an angiogenesis inhibitor, was increased in MI+ cancers (27

282 To rapidly discover clinically useful angiogenesis inhibitors, we created and screened a libra

283 whose goal was to discover novel endogenous angiogenesis inhibitors, we have purified matrilin-1 (MA

284 , to investigate mechanisms of resistance to angiogenesis inhibitors, we transduced human glioblastom

285 decreased expression of thrombospondin-1, an angiogenesis inhibitor, were also observed in ML.delta b

286 oteinases and also basement membrane-derived angiogenesis inhibitors when compared with wild-type tum

287 etic resonance imaging, and use of selective angiogenesis inhibitors will contribute to this understa

288 stration with endostatin (ES), an endogenous angiogenesis inhibitor with antitumor effects shown to i

289 Pigment epithelial-derived factor (PEDF), an angiogenesis inhibitor with neurotrophic properties, bal

290 utic limitation can be overcome by combining angiogenesis inhibitors with chemotherapeutic agents.

291 lung metastases and suggests that combining angiogenesis inhibitors with radiation therapy may contr